fibrosis

(redirected from Pulmonary fibrosis)
Also found in: Dictionary, Thesaurus, Medical.
Related to Pulmonary fibrosis: Idiopathic pulmonary fibrosis

fibrosis

the formation of an abnormal amount of fibrous tissue in an organ or part as the result of inflammation, irritation, or healing

fibrosis

[fī′brō·səs]
(medicine)
Growth of fibrous connective tissue in an organ or part in excess of that naturally present.
References in periodicals archive ?
Boston-Providence Pulmonary Fibrosis Care Centers (Beth Israel-Deaconess Medical Center, Massachusetts General Hospital, Rhode Island Hospital, St.
Companies discussed in this Pulmonary Fibrosis - Pipeline Review, H2 2014 report include AdAlta Pty Ltd.
In a review of CT scans of more than 2,600 adults who did not have a clinical diagnosis of pulmonary fibrosis, researchers found imaging evidence of lung inflammation and scarring in about 9 percent of those over age 50.
and a reticular nodular pattern in the lungs consistent with the known pulmonary fibrosis.
Because ACE inhibitors and statins are known to "modulate local fibroproliferative pathways in a variety of organ systems," the researchers reviewed the records of 478 pulmonary fibrosis patients to see whether those who were taking either type of drug for cardiovascular indications may have shown improved lung function, compared with patients who weren't.
Often, the disease resembles other chronic interstitial lung diseases such as idiopathic pulmonary fibrosis.
InterMune currently markets ACTIMMUNE(R) (Interferon gamma-1b) Injection in the United States for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis and is in Phase III clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and multidrug-resistant tuberculosis (MDR TB).
The exact number of people who develop idiopathic pulmonary fibrosis each year is not known.
A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Market Dynamix: Idiopathic Pulmonary Fibrosis is based on responses to an online survey of 100 IPF-treating pulmonologists and 15 in-depth qualitative interviews with international thought leaders conducted during the fourth quarter of 2015.
Idiopathic pulmonary fibrosis (IPF) is a progressive and severely debilitating lung disease with a high mortality rate.
This research gives us several new targets for investigation of pulmonary fibrosis ," David Schwartz, MD, senior author on the paper, Professor of Medicine at National Jewish Health and Chair of Medicine the University of Colorado School of Medicine, said.

Full browser ?